69 completed, 16 active not recruiting, 12 terminated, 4 unknown. 66 Phase 2, 35 Phase 1, 10 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow cediranib: new trials by email Literature Review of cediranib trials Research Report on cediranib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2020-07-28 | 2026-09-14 |
| WIRE - Novel Treatments in Renal Cell Cancer Olaparib, Cediranib, Volrustomig - Renal Cell Cancer | Phase 2 | Recruiting | CCTU- Cancer Theme | 134 | 2020-07-27 | 2026-09-25 |
| Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma Cediranib Maleate, Durvalumab - Uveal Melanoma, Metastatic Cancer | Phase 2 | Withdrawn | Grupo Español Multidisciplinar de Melanoma | 2020-05-01 | 2020-06-02 | |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors Durvalumab, Olaparib, Cediranib - Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 90 | 2019-04-08 | 2026-10-05 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer Cediranib, Olaparib - Cervical Cancer | Phase 2 | Active not recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 79 | 2018-10-09 | 2025-02-26 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 288 | 2018-09-27 | 2026-10-22 |
| Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients Olaparib, Cediranib - Ovarian Cancer | Phase 3 | Unknown | University College, London | 330 | 2018-06-15 | 2022-09-27 |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Paclitaxel, Cediranib, Olaparib - Carcinosarcoma, Endometrial Neoplasms | Phase 2 | Unknown | University of Manchester | 124 | 2018-05-17 | 2022-03-02 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer Cediranib - Bowel Obstruction, Ovarian Cancer | Phase 2 | Completed | Prof Gordon Jayson | 30 | 2018-05-14 | 2026-06-15 |
| Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Carboplatin, Cediranib, Cediranib Maleate - Extensive Stage Lung Small Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2018-03-30 | 2023-10-17 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 528 | 2017-12-18 | 2025-10-27 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Bevacizumab, Cediranib, Cediranib Maleate - Recurrent Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2017-12-07 | 2026-09-15 |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer Cediranib, Olaparib - Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2017-08-11 | 2026-07-31 |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib Paclitaxel, Cediranib, Olaparib - Ovarian Neoplasms | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 123 | 2017-06-12 | 2025-01-10 |
| Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer Olaparib, Cediranib, Platinum-based Chemotherapy - Ovarian Cancer | Early Phase 1 | Completed | The Christie NHS Foundation Trust | 28 | 2017-05-26 | 2022-02-22 |
| Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Olaparib, Cediranib, Paclitaxel - Ovarian Cancer | Phase 2 | Completed | University of Oxford | 139 | 2017-03-09 | 2024-01-23 |
| Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer cediranib and olaparib - Recurrent Platinum Resistant Ovarian Cancer | Phase 2 | Completed | AstraZeneca | 62 | 2017-01-17 | 2022-03-08 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-05-23 | 2026-09-29 |
Showing 20 of 104. Sign in to see all of them.
Ovarian Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (13) · Neoplasms (10) · Fallopian Tube Neoplasms (9) · Glioblastoma (9) · Breast Neoplasms (8) · Colorectal Neoplasms (8) · Lung Neoplasms (7) · Brain Neoplasms (6) · Carcinoma, Renal Cell (6) · Colonic Neoplasms (6) · Gliosarcoma (6) · Neoplasm Metastasis (6) · Rectal Neoplasms (6) · Melanoma (4)
National Cancer Institute (NCI) (47) · AstraZeneca (30) · NCIC Clinical Trials Group (4) · University College, London (3) · University Health Network, Toronto (3) · Alliance for Clinical Trials in Oncology (2) · The Christie NHS Foundation Trust (2) · CCTU- Cancer Theme (1) · Grupo Español Multidisciplinar de Melanoma (1) · Institute of Cancer Research, United Kingdom (1) · M.D. Anderson Cancer Center (1) · Mario Negri Institute for Pharmacological Research (1) · Medical Research Council (1) · Prof Gordon Jayson (1) · Radboud University Medical Center (1)
United States (58) · United Kingdom (25) · Canada (24) · Germany (8) · Australia (7) · Japan (6) · Netherlands (6) · Spain (6) · Austria (4) · Brazil (4) · Czechia (4) · France (4) · South Korea (4) · Belgium (3) · Italy (3)
Jane Robertson (10) · Nick Botwood, BSc, MBBS, MRCP, MFPM (5) · Jane Robertson, MD (3) · Joyce F Liu (3) · Scott A. Laurie, MD, FRCPC (3) · Alice P Chen, M.D. (2) · Amit Oza, M.D. (2) · Bijoyesh Mookerjee, MD (2) · Glenwood D. Goss, MD, BCh, FCP, FRCPC (2) · Jane Roberston (2) · Joseph W Kim (2) · Jung-min Lee (2) · Sebastien Hotte (2) · Alex A. Adjei, MD, PhD (1) · Andrew Clamp (1)
PMID 37185961, PMID 18398152, PMID 25113840, PMID 35170751, PMID 19203899, PMID 19228749, PMID 19917841, PMID 20458050, PMID 21060028, PMID 22285180, PMID 22831987, PMID 22891356, PMID 23197081, PMID 23232491, PMID 23362324, PMID 23419134, PMID 23510802, PMID 23630200, PMID 23801303, PMID 23810467, PMID 23940216, PMID 24309981, PMID 24360368, PMID 24714778, PMID 24788563, PMID 25218906, PMID 25895616, PMID 26179201, PMID 26802156, PMID 27025186, PMID 27232884, PMID 30514390, PMID 30679026, PMID 30738795, PMID 31160249, PMID 31345267, PMID 31378656, PMID 31386610, PMID 31502400, PMID 32444417, PMID 33097567, PMID 33452192, PMID 33610123, PMID 33842889, PMID 34794412, PMID 35063281, PMID 35290101, PMID 36256912, PMID 36302173, PMID 38127487
U10CA180868 (6), N01CM62201 (5), U01CA062490 (4), UM1CA186709 (4), 2016 (3), N01CM00071 (3), N01CM62203 (3), N01CM62209 (3), P30CA006516 (3), P30CA015083 (3), N01CM00038 (2), N01CM62205 (2), P30CA014599 (2), P30CA022453 (2), U01CA062487 (2)